Global Selective Cox-2 Inhibitors Market 2020 Research Forecast 2026

Published On: Dec 2019

Format: PDF

Publisher: QY Research

Pages: 113

Report ID: 372063

In 2020, the global Selective Cox-2 Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2026, with a CAGR of xx% during 2020-2026.

This report focuses on the global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Cox-2 Inhibitors development in United States, Europe and China.

The key players covered in this study
Boehringer-Ingelheim
TerSera Therapeutics
Iroko Pharmaceuticals
Apotex
Yung Shin Pharmaceutical
Breckenridge Pharmaceutical
Meda Pharmaceuticals
Cipla
Glenmark Pharmaceuticals
Teva
PuraCap Pharmaceutical
Almirall Limited
Lupin Pharmaceuticals
Aurobindo Pharma
Pfizer
Mylan
Shire Pharmaceuticals
Bayer
Novacap
Abbott
Geri-Care
Perrigo
Kopran
Merck
Hengrui pharmaceutical
Kelun Group
Qilu Pharmaceutical
Taro Pharmaceuticals 

Market segment by Type, the product can be split into
Meloxicam
Celecoxib
Etoricoxib
Imrecoxib
Etodolac
Parecoxib
Other

Market segment by Application, split into
Rheumatoid Arthritis
Osteoarthritis
Spondylosis Chronica Ankylopoietica
Other

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the Selective Cox-2 Inhibitors development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Selective Cox-2 Inhibitors are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (2015-2026)
1.4.2 Meloxicam
1.4.3 Celecoxib
1.4.4 Etoricoxib
1.4.5 Imrecoxib
1.4.6 Etodolac
1.4.7 Parecoxib
1.4.8 Other
1.5 Market by Application
1.5.1 Global Selective Cox-2 Inhibitors Market Share by Application (2015-2026)
1.5.2 Rheumatoid Arthritis
1.5.3 Osteoarthritis
1.5.4 Spondylosis Chronica Ankylopoietica
1.5.5 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Selective Cox-2 Inhibitors Market Size
2.2 Selective Cox-2 Inhibitors Growth Trends by Regions
2.2.1 Selective Cox-2 Inhibitors Market Size by Regions (2015-2026)
2.2.2 Selective Cox-2 Inhibitors Market Share by Regions (2015-2020)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Selective Cox-2 Inhibitors Market Size by by Players
3.1.1 Global Selective Cox-2 Inhibitors Revenue by by Players (2015-2020)
3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by by Players (2015-2020)
3.1.3 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
3.2 Selective Cox-2 Inhibitors Key Players Head office and Area Served
3.3 Key Players Selective Cox-2 Inhibitors Product/Solution/Service
3.4 Date of Enter into Selective Cox-2 Inhibitors Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Selective Cox-2 Inhibitors Market Size by Type (2015-2020)
4.2 Global Selective Cox-2 Inhibitors Market Size by Application (2015-2020)

5 United States
5.1 United States Selective Cox-2 Inhibitors Market Size (2015-2020)
5.2 Selective Cox-2 Inhibitors Key Players in United States
5.3 United States Selective Cox-2 Inhibitors Market Size by Type
5.4 United States Selective Cox-2 Inhibitors Market Size by Application

6 Europe
6.1 Europe Selective Cox-2 Inhibitors Market Size (2015-2020)
6.2 Selective Cox-2 Inhibitors Key Players in Europe
6.3 Europe Selective Cox-2 Inhibitors Market Size by Type
6.4 Europe Selective Cox-2 Inhibitors Market Size by Application

7 China
7.1 China Selective Cox-2 Inhibitors Market Size (2015-2020)
7.2 Selective Cox-2 Inhibitors Key Players in China
7.3 China Selective Cox-2 Inhibitors Market Size by Type
7.4 China Selective Cox-2 Inhibitors Market Size by Application

8 Japan
8.1 Japan Selective Cox-2 Inhibitors Market Size (2015-2020)
8.2 Selective Cox-2 Inhibitors Key Players in Japan
8.3 Japan Selective Cox-2 Inhibitors Market Size by Type
8.4 Japan Selective Cox-2 Inhibitors Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Selective Cox-2 Inhibitors Market Size (2015-2020)
9.2 Selective Cox-2 Inhibitors Key Players in Southeast Asia
9.3 Southeast Asia Selective Cox-2 Inhibitors Market Size by Type
9.4 Southeast Asia Selective Cox-2 Inhibitors Market Size by Application

10 India
10.1 India Selective Cox-2 Inhibitors Market Size (2015-2020)
10.2 Selective Cox-2 Inhibitors Key Players in India
10.3 India Selective Cox-2 Inhibitors Market Size by Type
10.4 India Selective Cox-2 Inhibitors Market Size by Application

11 Central & South America
11.1 Central & South America Selective Cox-2 Inhibitors Market Size (2015-2020)
11.2 Selective Cox-2 Inhibitors Key Players in Central & South America
11.3 Central & South America Selective Cox-2 Inhibitors Market Size by Type
11.4 Central & South America Selective Cox-2 Inhibitors Market Size by Application

12 International Players Profiles
12.1 Boehringer-Ingelheim
12.1.1 Boehringer-Ingelheim Company Details
12.1.2 Company Description and Business Overview
12.1.3 Selective Cox-2 Inhibitors Introduction
12.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.1.5 Boehringer-Ingelheim Recent Development
12.2 TerSera Therapeutics
12.2.1 TerSera Therapeutics Company Details
12.2.2 Company Description and Business Overview
12.2.3 Selective Cox-2 Inhibitors Introduction
12.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.2.5 TerSera Therapeutics Recent Development
12.3 Iroko Pharmaceuticals
12.3.1 Iroko Pharmaceuticals Company Details
12.3.2 Company Description and Business Overview
12.3.3 Selective Cox-2 Inhibitors Introduction
12.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.3.5 Iroko Pharmaceuticals Recent Development
12.4 Apotex
12.4.1 Apotex Company Details
12.4.2 Company Description and Business Overview
12.4.3 Selective Cox-2 Inhibitors Introduction
12.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.4.5 Apotex Recent Development
12.5 Yung Shin Pharmaceutical
12.5.1 Yung Shin Pharmaceutical Company Details
12.5.2 Company Description and Business Overview
12.5.3 Selective Cox-2 Inhibitors Introduction
12.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.5.5 Yung Shin Pharmaceutical Recent Development
12.6 Breckenridge Pharmaceutical
12.6.1 Breckenridge Pharmaceutical Company Details
12.6.2 Company Description and Business Overview
12.6.3 Selective Cox-2 Inhibitors Introduction
12.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.6.5 Breckenridge Pharmaceutical Recent Development
12.7 Meda Pharmaceuticals
12.7.1 Meda Pharmaceuticals Company Details
12.7.2 Company Description and Business Overview
12.7.3 Selective Cox-2 Inhibitors Introduction
12.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.7.5 Meda Pharmaceuticals Recent Development
12.8 Cipla
12.8.1 Cipla Company Details
12.8.2 Company Description and Business Overview
12.8.3 Selective Cox-2 Inhibitors Introduction
12.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.8.5 Cipla Recent Development
12.9 Glenmark Pharmaceuticals
12.9.1 Glenmark Pharmaceuticals Company Details
12.9.2 Company Description and Business Overview
12.9.3 Selective Cox-2 Inhibitors Introduction
12.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.9.5 Glenmark Pharmaceuticals Recent Development
12.10 Teva
12.10.1 Teva Company Details
12.10.2 Company Description and Business Overview
12.10.3 Selective Cox-2 Inhibitors Introduction
12.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2015-2020)
12.10.5 Teva Recent Development
12.11 PuraCap Pharmaceutical
12.12 Almirall Limited
12.13 Lupin Pharmaceuticals
12.14 Aurobindo Pharma
12.15 Pfizer
12.16 Mylan
12.17 Shire Pharmaceuticals
12.18 Bayer
12.19 Novacap
12.20 Abbott
12.21 Geri-Care
12.22 Perrigo
12.23 Kopran
12.24 Merck
12.25 Hengrui pharmaceutical
12.26 Kelun Group
12.27 Qilu Pharmaceutical
12.28 Taro Pharmaceuticals 

13 Market Forecast 2020-2026
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2020-2026)
13.10 Market Size Forecast by Application (2020-2026)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details